NCT06854939View on ClinicalTrials.gov

A Prospective Study Investigating the Relationship Between Minimal Residual Disease Detection, Monitoring Frequency, and Prognosis in Non-small Cell Lung Cancer Patients Eligible for Curative Treatment.

Not yet recruitingOBSERVATIONAL
Enrollment

350

Participants

Timeline

Start Date

March 1, 2025

Primary Completion Date

September 30, 2026

Study Completion Date

September 30, 2029

Conditions
NSCLC, Stage I, II, III
Trial Locations (1)

Unknown

National Cancer Center Hospital, Chuo-ku

Sponsors

Collaborators (1)

Natera, Inc.
All Listed Sponsors
collaborator

Natera, Inc.

INDUSTRY

lead

National Cancer Center, Japan

OTHER_GOV

NCT06854939 - A Prospective Study Investigating the Relationship Between Minimal Residual Disease Detection, Monitoring Frequency, and Prognosis in Non-small Cell Lung Cancer Patients Eligible for Curative Treatment. | Biotech Hunter | Biotech Hunter